Axsome Therapeutics, Inc. (AXSM) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Axsome Therapeutics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.638 -- 00:00:06.106 Good morning and welcome to the Axiom Therapeutics third quarter 2025 earnings conference 00:00:06.106 -- 00:00:11.033 call. My name is Daryl and I will be your operator for today's call. 00:00:11.033 -- 00:00:14.438 At this time, all participants are in a listen-only mode. 00:00:14.438 -- 00:00:17.922 Later, there will be a question and answer session and instructions will be given at 00:00:17.922 -- 00:00:22.349 that time. Please note that this call is being recorded. 00:00:22.349 -- 00:00:25.934 I would now like to hand the call over to Darren Oplin, Senior Director of Corporate 00:00:25.934 -- 00:00:28.878 Communications. Please go ahead. 00:00:28.878 -- 00:00:33.065 Thank you, Daryl. Good morning, everyone. Thank you for joining us for ACTSOM's Third 00:00:33.065 -- 00:00:37.812 Quarter 2025 Earnings Conference Call. With us today are Dr. 00:00:37.812 -- 00:00:43.540 Ariel Tabito, our Chief Executive Officer, Nick Pizzi, our Chief Financial Officer, 00:00:43.540 -- 00:00:49.108 and Ari Maisel, our Chief Commercial Officer, who will begin our call with prepared remarks. 00:00:49.108 -- 00:00:53.915 Marcus Jacobson, our Chief Operating Officer, and Hunter Murdoch, our General Counsel, 00:00:53.915 -- 00:00:57.100 will also be available for Q&A. 00:00:57.100 -- 00:00:59.340 This morning, 00:01:09.033 -- 00:01:11.776 to today's call. 00:01:11.776 -- 00:01:15.661 Please note that today's discussion includes forward-looking statements regarding our 00:01:15.661 -- 00:01:20.748 financial performance, commercial strategy, and operational plans, including 00:01:20.748 -- 00:01:24.613 research, development, and regulatory activities. 00:01:24.613 -- 00:01:29.118 These statements are based on current expectations and assumptions and are ...